Phenotype Proteome final neu

Biocrates Life Sciences AG, internationally renowned developer of targeted metabolic phenotyping solutions, supports the discovery and validation of biomarkers for complex multifactorial diseases in pre-clinical and clinical research.

Biocrates offers the possibility to identify potential biomarkers for diagnostic investigation as well as drug therapy monitoring. With its mass spectrometry based products the company is providing tools for a comprehensive insight into pathways and metabolic signatures of diseases (such as cancer or neurodegenerative diseases).

 

The company's reproducible and quantitative kits and services  analyze more than 630 endogenous metabolites under quality-controlled conditions, and can be used with a wide range of species and biological matrices.

An advanced proprietary software solution is used to manage the entire analysis workflow, while enhancing the standardization and harmonization of project data processing.

Founders

Biocrates was founded in Innsbruck in 2002 by 3 leading university professors (Günther Bonn, Adelbert Roscher, Hartmut Glossmann) from Munich and Innsbruck as well as Bionorica, a German phytocompany.

 

Areas of Application

Metabolic phenotyping data allow detailed metabolic pathway analysis and identification of potential drug targets as well as their mode of action. Additionally, these results provide targets for individual therapy and disease prediction. In combination with other “omics”-techniques metabolic phenotyping supports the identification of gene functions and provides a complete system biological diagnosis for an improved personalized medicine approach.